<DOC>
	<DOCNO>NCT00006123</DOCNO>
	<brief_summary>RATIONALE : Chemotherapy us different way stop tumor cell divide stop grow die . Combining chemotherapy peripheral stem cell transplantation may allow doctor give high dos chemotherapy drug kill tumor cell . Monoclonal antibody trastuzumab locate tumor cell either kill deliver tumor-killing substance without harm normal cell . PURPOSE : Phase I/II trial study effectiveness chemotherapy peripheral stem cell transplantation follow trastuzumab treat woman metastatic breast cancer .</brief_summary>
	<brief_title>Chemotherapy Peripheral Stem Cell Transplantation Followed Trastuzumab Treating Women With Metastatic Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine safety toxicity profile , specifically cardiac toxicity , trastuzumab ( Herceptin ) follow high dose chemotherapy autologous peripheral blood stem cell transplantation woman metastatic breast cancer . II . Determine time disease progression disease free survival patient treat regimen . III . Determine impact trastuzumab ( Herceptin ) minimal residual disease autologous peripheral blood stem cell transplantation evidence serial immunocytochemical analysis bone marrow . IV . Determine relationship posttransplant reconstitution antibody dependent cellular toxicity efficacy trastuzumab ( Herceptin ) patient . OUTLINE : This multicenter study . Patients undergo stem cell mobilization growth factor alone ( filgrastim ( G-CSF ) and/or sargramostim ( GM-CSF ) ) chemotherapy follow growth factor ( depend center ) . Peripheral blood stem cell ( PBSC ) collect leukapheresis . Patients receive high dose chemotherapy consist cyclophosphamide IV 1 hour cisplatin IV 72 hour day -6 -4 carmustine IV day -3 cyclophosphamide IV , thiotepa IV , carboplatin IV 96 hour day -7 -4 ( depend center ) . PBSC reinfused day 0 . Patients receive trastuzumab IV 30-90 minute weekly 1 year disease progression begin 5-8 week PBSC reinfusion . PROJECTED ACCRUAL : A total 70 patient accrue study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Thiotepa</mesh_term>
	<mesh_term>Carmustine</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm stage IV breast cancer overexpresses HER2/neu Evidence least partial response ( least 50 % reduction ) salvage chemotherapy initial chemotherapy metastatic disease Measurable disease require disease progression induction chemotherapy Bone lesions site metastatic disease allow evidence clinical improvement new lesion xray No CNS metastases Hormone receptor status : Not specify PATIENT CHARACTERISTICS : Age : 18 physiologic 65 Sex : Female Menopausal status : Pre postmenopausal Performance status : Karnofsky 80100 % Life expectancy : At least 6 month Hematopoietic : WBC least 2,500/mm3 Absolute neutrophil count least 1,000/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin great 1.5 time upper limit normal ( ULN ) SGOT great 2.5 time ULN Renal : Creatinine great 2.0 mg/dL Cardiovascular : LVEF least 45 % radionucleotide ventriculogram No uncontrolled hypertension No unstable angina No New York Heart Association class IV heart disease congestive heart failure No coronary angioplasty myocardial infarction within past 6 month No uncontrolled atrial ventricular cardiac arrhythmia Pulmonary : FEV1 DLCO least 50 % Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception HIV negative No insulin dependent diabetes mellitus No uncontrolled active systemic infection No significant nonmalignant disease No malignancy past 5 year except surgically cure nonmelanoma skin cancer carcinoma situ cervix PRIOR CONCURRENT THERAPY : Biologic therapy : Prior trastuzumab allow No prior bone marrow peripheral blood stem cell transplantation Chemotherapy : See Disease Characteristics Prior doxorubicin exceed total cumulative dose 360 mg/m2 No 6 standard course pretransplant salvage chemotherapy No 3 month prior weekly taxane therapy More 1 chemotherapy regimen allow progression chemotherapy Endocrine therapy : Concurrent tamoxifen therapy allow estrogen receptor positive patient receive prior hormonal therapy No concurrent hormonal therapy Radiotherapy : No concurrent radiotherapy Surgery : Not specify Other : Concurrent pamidronate allow bone lesion</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2006</verification_date>
	<keyword>stage IV breast cancer</keyword>
</DOC>